Immune reconstitution and vaccination outcome in HIV-1 infected children: Present knowledge and future directions

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 12, 2012, Pages 1784-1794

  Cagigi, Alberto ^a   Cotugno, Nicola ^b   Giaquinto, Carlo ^c   Nicolosi, Luciana ^a   Bernardi, Stefania ^a   Rossi, Paolo ^a,b   Douagi, Iyadh ^d   Palma, Paolo ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

AIDS; HAART; Immunization schedule; Protective immune responses; Vertical infection

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MUMPS VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; RUBELLA VACCINE; TETANUS TOXIN;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CHILD; DRUG CLASSIFICATION; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG PREFERENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; ONSET AGE; POLIOMYELITIS; REVACCINATION; REVIEW; VACCINATION; VIRUS INHIBITION; VIRUS REPLICATION;

AIDS; HAART; IMMUNIZATION SCHEDULE; PROTECTIVE IMMUNE RESPONSES; VERTICAL INFECTION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; INDIVIDUALIZED MEDICINE; TREATMENT OUTCOME; VACCINATION; VACCINES;

EID: 84872244258     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21827     Document Type: Review

References (129)

1. Zinkernagel RM. On immunological memory. Philos Trans R Soc Lond B Biol Sci 2000; 355:369-71; PMID:10794057; http://dx.doi.org/10.1098/rstb.2000.0576.
2. Muehlinghaus G, Cigliano L, Huehn S, Peddinghaus A, Leyendeckers H, Hauser AE, et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005; 105:3965-71; PMID:15687242; http://dx.doi.org/10.1182/blood-2004-08-2992.
3. McHeyzer-Williams MG, Ahmed R. B cell memory and the long-lived plasma cell. Curr Opin Immunol 1999; 11:172-9; PMID:10322151; http://dx.doi.org/10. 1016/S0952-7915(99)80029-6.
4. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95-8; PMID:11986671; http://dx.doi.org/10.1038/417095a.
5. Ladell K, Hellerstein MK, Cesar D, Busch R, Boban D, McCune JM. Central memory CD8+ T cells appear to have a shorter lifespan and reduced abundance as a function of HIV disease progression. J Immunol 2008; 180:7907-18; PMID:18523254.
6. Schenal M, Lo Caputo S, Fasano F, Vichi F, Saresella M, Pierotti P, et al. Distinct patterns of HIV-specific memory T lymphocytes in HIV-exposed uninfected individuals and in HIV-infected patients. AIDS 2005; 19:653-61; PMID:15821391; http://dx.doi.org/10.1097/01.aids.0000166088.85951.25.
7. Ho HN, Hultin LE, Mitsuyasu RT, Matud JL, Hausner MA, Bockstoce D, et al. Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 1993; 150:3070-9; PMID:8454874.
8. Kestens L, Vanham G, Vereecken C, Vandenbruaene M, Vercauteren G, Colebunders RL, et al. Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection. Clin Exp Immunol 1994; 95:436-41; PMID:7907956; http://dx.doi.org/10.1111/j.1365-2249.1994.tb07015.x.
9. Böhler T, Herr I, Debatin KM, Geiss M, Haas J. Downregulation of increased CD95 (APO-1/Fas) ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy. Blood 1997; 90:886-8; PMID:9226190.
10. Debatin KM, Fahrig-Faissner A, Enenkel-Stoodt S, Kreuz W, Benner A, Krammer PH. High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children. Blood 1994; 83:3101-3; PMID:7514053.
11. Bäumler CB, Böhler T, Herr I, Benner A, Krammer PH, Debatin KM. Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children. Blood 1996; 88:1741-6; PMID:8781430.
12. Giorgi JV, Hausner MA, Hultin LE. Detailed immunophenotype of CD8+ memory cytotoxic T-lymphocytes (CTL) against HIV-1 with respect to expression of CD45RA/RO, CD62L and CD28 antigens. Immunol Lett 1999; 66:105-10; PMID:10203041; http://dx.doi.org/10.1016/S0165-2478(98)00170-9.
13. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-8; PMID:12960820; http://dx.doi.org/10. 1097/00002030-200309050-00006.
14. De Milito A, Mörch C, Sönnerborg A, Chiodi F. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS 2001; 15:957-64; PMID:11399977; http://dx.doi.org/10.1097/00002030-200105250-00003.
15. Cagigi A, Palma P, Nilsson A, Di Cesare S, Pensieroso S, Kakoulidou M, et al. The impact of active HIV-1 replication on the physiological age-related decline of immature-transitional B-cells in HIV-1 infected children. AIDS 2010; 24:2075-80; PMID:20588160; http://dx.doi.org/10.1097/QAD.0b013e32833c3298.
16. Malaspina A, Moir S, Ho J, Wang W, Howell ML, O'Shea MA, et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A 2006; 103:2262-7; PMID:16461915; http://dx.doi.org/10.1073/pnas.0511094103.
17. Titanji K, De Milito A, Cagigi A, Thorstensson R, Grützmeier S, Atlas A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006; 108:1580-7; PMID:16645169; http://dx.doi.org/10.1182/blood-2005-11-013383.
18. Cagigi A, Nilsson A, De Milito A, Chiodi F. B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design. Vaccine 2008; 26:3016-25; PMID:18164520; http://dx.doi.org/10.1016/j.vaccine.2007.11.063.
19. Lefevre EA, Krzysiek R, Loret EP, Galanaud P, Richard Y. Cutting edge: HIV-1 Tat protein differentially modulates the B cell response of naive, memory, and germinal center B cells. J Immunol 1999; 163:1119-22; PMID:10415004.
20. He B, Qiao X, Klasse PJ, Chiu A, Chadburn A, Knowles DM, et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006; 176:3931-41; PMID:16547227.
21. Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006; 7:302-10; PMID:16429138; http://dx.doi.org/10.1038/ni1302.
22. Cagigi A, Du L, Dang LV, Grutzmeier S, Atlas A, Chiodi F, et al. CD27(-) B-cells produce class switched and somatically hyper-mutated antibodies during chronic HIV-1 infection. PLoS One 2009; 4:e5427; PMID:19412542; http://dx.doi.org/10.1371/journal.pone.0005427.
23. De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, Narita M, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 2004; 103:2180-6; PMID:14604962; http://dx.doi.org/10.1182/blood-2003-07-2375.
24. Shirai A, Cosentino M, Leitman-Klinman SF, Klinman DM. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest 1992; 89:561-6; PMID:1737846; http://dx.doi.org/10.1172/JCI115621.
25. Martínez-Maza O, Breen EC. B-cell activation and lymphoma in patients with HIV. Curr Opin Oncol 2002; 14:528-32; PMID:12192272; http://dx.doi.org/10.1097/00001622-200209000-00009.
26. Fournier AM, Fondere JM, Alix-Panabieres C, Merle C, Baillat V, Huguet MF, et al. Spontaneous secretion of immunoglobulins and anti-HIV-1 antibodies by in vivo activated B lymphocytes from HIV-1-infected subjects: monocyte and natural killer cell requirement for in vitro terminal differentiation into plasma cells. Clin Immunol 2002; 103:98-109; PMID:11987990; http://dx.doi.org/ 10.1006/clim.2001.5195.
27. Shearer WT, Easley KA, Goldfarb J, Jenson HB, Rosenblatt HM, Kovacs A, et al.; P2C2 HIV Study Group. Evaluation of immune survival factors in pediatric HIV-1 infection. Ann N Y Acad Sci 2000; 918:298-312; PMID:11144332; http://dx.doi.org/10.1111/j.1749-6632.2000.tb05499.x.
28. Moir S, Malaspina A, Ogwaro KM, Donoghue ET, Hallahan CW, Ehler LA, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A 2001; 98:10362-7; PMID:11504927; http://dx.doi.org/10.1073/pnas.181347898.
29. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O'Shea MA, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 2008; 205:1797-805; PMID:18625747; http://dx.doi.org/10.1084/jem.20072683.
30. Moir S, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 2008; 122:12-9, quiz 20-1; PMID:18547629; http://dx.doi.org/10.1016/j.jaci.2008.04.034.
31. Cagigi A, Mowafi F, Phuong Dang LV, Tenner-Racz K, Atlas A, Grutzmeier S, et al. Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection. Blood 2008; 112:4401-10; PMID:18780835; http://dx.doi.org/10.1182/blood-2008-02-140426.
32. Badr G, Borhis G, Treton D, Moog C, Garraud O, Richard Y. HIV type 1 glycoprotein 120 inhibits human B cell chemotaxis to CXC chemokine ligand (CXCL) 12, CC chemokine ligand (CCL)20, and CCL21. J Immunol 2005; 175:302-10; PMID:15972662.
33. Cagigi A, Nilsson A, Pensieroso S, Chiodi F. Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. Lancet Infect Dis 2010; 10:499-503; PMID:20610332; http://dx.doi.org/10.1016/S1473-3099(10)70117-1.
34. Moir S, Malaspina A, Ho J, Wang W, Dipoto AC, O'Shea MA, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis 2008; 197:572-9; PMID:18240953; http://dx.doi.org/10.1086/526789.
35. Faye A, Le Chenadec J, Dollfus C, Thuret I, Douard D, Firtion G, et al.; French Perinatal Study Group. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis 2004; 39:1692-8; PMID:15578372; http://dx.doi.org/10.1086/425739.
36. Pensieroso S, Cagigi A, Palma P, Nilsson A, Capponi C, Freda E, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci U S A 2009; 106:7939-44; PMID:19416836; http://dx.doi.org/10.1073/pnas.0901702106.
37. Palma P, Romiti ML, Cancrini C, Pensieroso S, Montesano C, Bernardi S, et al. Delayed early anti-retroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants. Vaccine 2008; 26:5196-201; PMID:18471944; http://dx.doi.org/10.1016/j.vaccine.2008.03.062.
38. Zanchetta M, Anselmi A, Vendrame D, Rampon O, Giaquinto C, Mazza A, et al. Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response. Antivir Ther 2008; 13:47-55; PMID:18389898.
39. Romiti ML, Cancrini C, Castelli-Gattinara G, Di Cesare S, Ciaffi P, Bernardi S, et al. Kinetics of the T-cell receptor CD4 and CD8 V beta repertoire in HIV-1 vertically infected infants early treated with HAART. AIDS 2001; 15:2075-84; PMID:11684926; http://dx.doi.org/10.1097/00002030-200111090-00002.
40. Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis 2004; 4:510-8; PMID:15288824; http://dx.doi.org/10.1016/S1473-3099(04)01106-5.
41. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8:477-89; PMID:18652994; http://dx.doi.org/10.1016/ S1473-3099(08)70180-4.
42. Pichichero ME. Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics 2009; 124:1633-41; PMID:19933727; http://dx.doi.org/10.1542/peds.2008-3645.
43. Menson EN, Mellado MJ, Bamford A, Castelli G, Duiculescu D, Marczynska M, et al.; Paediatric European Network for Treatment of AIDS (PENTA) Vaccines Group; PENTA Steering Committee; Children's HIV Association (CHIVA). Guidance on vaccination of HIV-infected children in Europe. HIV Med 2012; 13:333-6, e1-14; PMID:22296225; http://dx.doi.org/10.1111/j.1468-1293.2011.00982.x.
44. Geretti AM, Doyle T. Immunization for HIV-positive individuals. Curr Opin Infect Dis 2010; 23:32-8; PMID:19949327; http://dx.doi.org/10.1097/QCO. 0b013e328334fec4.
45. Cotugno N, Douagi I, Rossi P, Palma P. Suboptimal Immune Reconstitution in Vertically HIV Infected Children: A View on How HIV Replication and Timing of HAART Initiation Can Impact on T and B-cell Compartment. Clin Dev Immunol 2012; 2012:805151.
46. Lesinski GB, Westerink MA. Vaccines against polysaccharide antigens. Curr Drug Targets Infect Disord 2001; 1:325-34; PMID:12455405; http://dx.doi.org/10. 2174/1568005014605964.
47. Arpadi SM, Markowitz LE, Baughman AL, Shah K, Adam H, Wiznia A, et al. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Pediatrics 1996; 97:653-7; PMID:8628602.
48. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 1994; 8:469-76; PMID:7912086; http://dx.doi.org/10.1097/00002030-199404000-00008.
49. Janoff EN, Douglas JM Jr., Gabriel M, Blaser MJ, Davidson AJ, Cohn DL, et al. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type J Infect Dis 1988; 158:983-90; PMID:3183430; http://dx.doi.org/10.1093/infdis/158.5.983.
50. Janoff EN, Hardy WD, Smith PD, Wahl SM. Humoral recall responses in HIV infection. Levels, specificity, and affinity of antigen-specific IgG. J Immunol 1991; 147:2130-5; PMID:1918947.
51. Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, et al.; Advisory Committee on Immunization Practices (ACIP). Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-3):1-34; PMID:16557217.
52. Ching N, Deville JG, Nielsen KA, Ank B, Wei LS, Sim MS, et al. Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART). Eur J Pediatr 2007; 166:51-6; PMID:16868780; http://dx.doi.org/10.1007/s00431-006-0184-2.
53. Zaccarelli-Filho CA, Ono E, Machado DM, Brunialti M, Succi RC, Salomão R, et al. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression. Cytometry B Clin Cytom 2007; 72:14-21; PMID:17041945; http://dx.doi.org/10.1002/cyto.b.20152.
54. Ghosh S, Feyen O, Jebran AF, Huck K, Jetzek-Zader M, Bas M, et al. Memory B cell function in HIV-infected children-decreased memory B cells despite ART. Pediatr Res 2009; 66:185-90; PMID:19390488; http://dx.doi.org/10.1203/PDR. 0b013e3181aa057d.
55. Essajee SM, Kim M, Gonzalez C, Rigaud M, Kaul A, Chandwani S, et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS 1999; 13:2523-32; PMID:10630521; http://dx.doi.org/10.1097/00002030-199912240-00005.
56. Rosenblatt HM, Song LY, Nachman SA, Stanley KE, Krogstad PA, Johnson GM, et al.; Pediatric Aids Clinical Trials Group 377 Study Team. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol 2005; 116:698-703; PMID:16159645; http://dx.doi.org/10.1016/j.jaci.2005.05.016.
57. Abzug MJ, Song LY, Fenton T, Nachman SA, Levin MJ, Rosenblatt HM, et al.; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 Protocol Team. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics 2007; 120:e1190-202; PMID:17938165; http://dx.doi.org/10.1542/peds.2007-0729.
58. Luzuriaga K, McManus M, Catalina M, Mayack S, Sharkey M, Stevenson M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000; 74:6984-91; PMID:10888637; http://dx.doi.org/ 10.1128/JVI.74.15.6984-6991.2000.
59. Rigaud M, Borkowsky W, Muresan P, Weinberg A, Larussa P, Fenton T, et al.; Pediatrics AIDS Clinical Trials Group P1006 Team. Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy. J Infect Dis 2008; 198:1123-30; PMID:18752430; http://dx.doi.org/10. 1086/592050.
60. Farquhar C, Wamalwa D, Selig S, John-Stewart G, Mabuka J, Majiwa M, et al. Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination. Pediatr Infect Dis J 2009; 28:295-9; PMID:19258919; http://dx.doi.org/10.1097/INF.0b013e3181903ed3.
61. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 2003; 111:e641-4; PMID:12777579; http://dx.doi.org/10.1542/peds.111.6.e641.
62. Vigano A, Vella S, Saresella M, Vanzulli A, Bricalli D, Di Fabio S, et al. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS 2000; 14:251-61; PMID:10716501; http://dx.doi.org/10.1097/00002030-200002180-00007.
63. Blazevic V, Jankelevich S, Steinberg SM, Jacobsen F, Yarchoan R, Shearer GM. Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responses. Clin Diagn Lab Immunol 2001; 8:943-8; PMID:11527808.
64. Hainaut M, Ducarme M, Schandene L, Peltier CA, Marissens D, Zissis G, et al. Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2003; 22:62-9; PMID:12544411; http://dx.doi.org/10.1097/00006454- 200301000-00016.
65. Peruzzi M, Azzari C, Galli L, Vierucci A, De Martino M. Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virological failure. Clin Exp Immunol 2002; 128:365-71; PMID:11985529; http://dx.doi.org/10.1046/j.1365-2249.2002.01814.x.
66. Pearce JM. Salk and Sabin: poliomyelitis immunisation. J Neurol Neurosurg Psychiatry 2004; 75:1552; PMID:15489385; http://dx.doi.org/10.1136/jnnp.2003. 028530.
67. Ryder RW, Oxtoby MJ, Mvula M, Batter V, Baende E, Nsa W, et al. Safety and immunogenicity of bacille Calmette-Guérin, diphtheria-tetanus- pertussis, and oral polio vaccines in newborn children in Zaire infected with human immunodeficiency virus type 1. J Pediatr 1993; 122:697-702; PMID:8496745; http://dx.doi.org/10.1016/S0022-3476(06)80007-7.
68. American Academy of Pediatrics Committee on Infectious Diseases. Poliomyelitis prevention: recommendations for use of inactivated poliovirus vaccine and live oral poliovirus vaccine. Pediatrics 1997; 99:300-5; PMID:9024465; http://dx.doi.org/10.1542/peds.99.2.300.
69. CDC issues guidelines for protection against viral hepatitis. Clin Pharm 1990; 9:670; PMID:2171865.
70. Fernandes SJ, Slhessarenko N, Souto FJ. Effects of vertical HIV infection on the persistence of anti-HBs after a schedule of three doses of recombinant hepatitis B vaccine. Vaccine 2008; 26:1032-7; PMID:18242796; http://dx.doi.org/10.1016/j.vaccine.2007.12.020.
71. Pippi F, Bracciale L, Stolzuoli L, Giaccherini R, Montomoli E, Gentile C, et al. Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania. HIV Med 2008; 9:519-25; PMID:18554311; http://dx.doi.org/10.1111/j.1468-1293.2008.00598.x.
72. Lao-araya M, Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine 2007; 25:5324-9; PMID:17566615; http://dx.doi.org/10.1016/j.vaccine.2007.05.006.
73. Abzug MJ, Warshaw M, Rosenblatt HM, Levin MJ, Nachman SA, Pelton SI, et al.; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2009; 200:935-46; PMID:19663708; http://dx.doi.org/10.1086/605448.
74. Couch RB. Seasonal inactivated influenza virus vaccines. Vaccine 2008; 26(Suppl 4):D5-9; PMID:18602728; http://dx.doi.org/10.1016/j.vaccine.2008.05. 076.
75. Nasal spray flu vaccine approved for 2-5 year olds. Child Health Alert 2007; 25:1; PMID:18273926.
76. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30:1993-8; PMID:22226861; http://dx.doi.org/10.1016/j.vaccine. 2011.12.098.
77. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; CD004879; PMID:18425905.
78. Murasko DM, Bernstein ED, Gardner EM, Gross P, Munk G, Dran S, et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002; 37:427-39; PMID:11772530; http://dx.doi.org/10.1016/S0531-5565(01)00210-8.
79. Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B; Pediatric AIDS Clinical Trials Group 265 Team. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis 2006; 194:247-55; PMID:16779732; http://dx.doi.org/10.1086/ 505149.
80. Amendola A, Pariani E, Viganò A, Erba P, Zappa A, Giacomet V, et al. Influenza surveillance in a cohort of HIV-infected children and adolescents immunized against seasonal influenza. Vaccine 2010; 28:2700-4; PMID:20105427; http://dx.doi.org/10.1016/j.vaccine.2010.01.021.
81. Tanzi E, Esposito S, Bojanin J, Amendola A, Trabattoni D, Pariani E, et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006; 78:440-5; PMID:16482542; http://dx.doi.org/10.1002/jmv.20559.
82. Montoya CJ, Toro MF, Aguirre C, Bustamante A, Hernandez M, Arango LP, et al. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 2007; 102:501-8; PMID:17612772; http://dx.doi.org/10.1590/S0074-02762007005000055.
83. Viganò A, Zuccotti GV, Pacei M, Erba P, Castelletti E, Giacomet V, et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 48:289-96; PMID:18545155; http://dx.doi.org/10.1097/ QAI.0b013e3181632cda.
84. Kieny MP. WHO supports fair access to influenza A (H1N1) vaccine. Bull World Health Organ 2009; 87:653-4; PMID:19784443; http://dx.doi.org/10.2471/BLT. 09.030909.
85. CDC issues guidance for HIV patients regarding H1N1 flu virus. AIDS Alert 2009; 24:64-5; PMID:19548329.
86. Palma P, Romiti ML, Bernardi S, Pontrelli G, Mora N, Santilli V, et al. Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. Biologicals 2012; 40:134-9; PMID:22261282; http://dx.doi.org/10.1016/j.biologicals.2011.12.001.
87. Hakim H, Allison KJ, Van De Velde LA, Li Y, Flynn PM, McCullers JA. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. Vaccine 2012; 30:879-85; PMID:22155630; http://dx.doi.org/10.1016/j.vaccine.2011.11.105.
88. Miraglia JL, Abdala E, Hoff PM, Luiz AM, Oliveira DS, Saad CG, et al. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS One 2011; 6:e27214; PMID:22087267; http://dx.doi.org/10.1371/journal.pone. 0027214.
89. Launay O, Desaint C, Durier C, Loulergue P, Duval X, Jacomet C, et al.; ANRS 151 HIFLUVAC Study Group and the French Clinical Vaccinology Network (Réseau National d'Investigation Clinique en Vaccinologie REIVAC). Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis 2011; 204:124-34; PMID:21628666; http://dx.doi.org/10.1093/ infdis/jir211.
90. Pallikkuth S, Pilakka Kanthikeel S, Silva SY, Fischl M, Pahwa R, Pahwa S. Upregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy. J Immunol 2011; 186:6173-81; PMID:21531891; http://dx.doi.org/10.4049/jimmunol.1100264.
91. American Academy of Pediatrics. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000; 106:362-6; PMID:10920169.
92. Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother 2012; 8:161-73; PMID:22426374; http://dx.doi.org/10.4161/hv.18432.
93. Kamchaisatian W, Wanwatsuntikul W, Sleasman JW, Tangsinmankong N. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children. J Allergy Clin Immunol 2006; 118:1336-41; PMID:17157665; http://dx.doi.org/10.1016/j.jaci.2006.09.036.
94. Tangsinmankong N, Kamchaisatian W, Day NK, Sleasman JW, Emmanuel PJ. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy. Ann Allergy Asthma Immunol 2004; 92:558-64; PMID:15191025; http://dx.doi.org/10. 1016/S1081-1206(10)61764-4.
95. Tarragó D, Casal J, Ruiz-Contreras J, Ramos JT, Rojo P, Snippe H, et al.; Spanish Network Pneumococcus Study Group. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol 2005; 12:165-70; PMID:15643002.
96. Costa IdeC, Guilardi F, Kmiliauskis MA, Arslanian C, Baldacci ER. Evaluation of humoral response to heptavalent pneumococcal conjugate vaccine in HIV-infected children. Rev Saude Publica 2008; 42:844-50; PMID:18797574; http://dx.doi.org/10.1590/S0034-89102008005000048.
97. Abzug MJ, Pelton SI, Song LY, Fenton T, Levin MJ, Nachman SA, et al.; Pediatric AIDS Clinical Trials Group P1024 Protocol Team. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25:920-9; PMID:17006288; http://dx.doi.org/10.1097/01.inf. 0000237830.33228.c3.
98. Iwajomo OH, Finn A, Moons P, Nkhata R, Sepako E, Ogunniyi AD, et al. Deteriorating pneumococcal-specific B-cell memory in minimally symptomatic African children with HIV infection. J Infect Dis 2011; 204:534-43; PMID:21791655; http://dx.doi.org/10.1093/infdis/jir316.
99. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71; PMID:17115046; http://dx.doi.org/10.1038/ nm1511.
100. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 2005; 23:2222-7; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051.
101. Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P, et al.; IMPAACT P1065 Protocol Team. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. Pediatr Infect Dis J 2012; 31:47-52; PMID:21987006; http://dx.doi.org/10.1097/INF.0b013e318236c67b.
102. Bar-On ES, Goldberg E, Fraser A, Vidal L, Hellmann S, Leibovici L. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Database Syst Rev 2009; CD005530; PMID:19588375.
103. Moreton J. MMR vaccination: protecting our children. J Fam Health Care 2002; 12:31; PMID:12415749.
104. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007; 45:637-42; PMID:17683001; http://dx.doi.org/10.1086/520651.
105. Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics 2006; 118:e315-22; PMID:16847077; http://dx.doi.org/10.1542/peds.2005-2616.
106. Ovsyannikova IG, Dhiman N, Jacobson RM, Vierkant RA, Poland GA. Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol 2003; 10:411-6; PMID:12738640.
107. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis 2001; 32:1090-4; PMID:11264038; http://dx.doi.org/10.1086/319591.
108. Lima M, De Menezes Succi RC, Nunes Dos Santos AM, Weckx LY, De Moraes-Pinto MI. Rubella immunization in human immunodeficiency virus type 1-infected children: cause for concern in vaccination strategies. Pediatr Infect Dis J 2004; 23:604-7; PMID:15247596; http://dx.doi.org/10.1097/01.inf. 0000128780.79145.5c.
109. Bekker V, Westerlaken GH, Scherpbier H, Alders S, Zaaijer H, van Baarle D, et al. Varicella vaccination in HIV-1-infected children after immune reconstitution. AIDS 2006; 20:2321-9; PMID:17117018; http://dx.doi.org/10.1097/ QAD.0b013e3280113f29.
110. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:1339-45; PMID:7475776; http://dx.doi.org/10.1016/S0140-6736(95)92348-9.
111. Vekemans J, Amedei A, Ota MO, D'Elios MM, Goetghebuer T, Ismaili J, et al. Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Eur J Immunol 2001; 31:1531-5; PMID:11465110; http://dx.doi.org/10.1002/1521-4141(200105)31:5〈1531::AID- IMMU1531〉3.0.CO;2-1.
112. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19:93-129; PMID:11244032; http://dx.doi.org/10.1146/annurev.immunol.19.1.93.
113. Zhang SY, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 2008; 226:29-40; PMID:19161414; http://dx.doi.org/10.1111/ j.1600-065X.2008.00698.x.
114. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 2007; 82:193-6; PMID:17526121.
115. Bhat GJ, Diwan VK, Chintu C, Kabika M, Masona J. HIV, BCG and TB in children: a case control study in Lusaka, Zambia. J Trop Pediatr 1993; 39:219-23; PMID:8411315.
116. Rabie H, Violari A, Duong T, Madhi SA, Josipovic D, Innes S, et al.; CHER team. Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis. [i.]. Int J Tuberc Lung Dis 2011; 15:1194-200, i; PMID:21943845; http://dx.doi.org/10.5588/ijtld.10. 0721.
117. Kagina BM, Abel B, Bowmaker M, Scriba TJ, Gelderbloem S, Smit E, et al. Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine 2009; 27:5488-95; PMID:19616494; http://dx.doi.org/10.1016/j.vaccine.2009.06.103.
118. Widney DP, Breen EC, Boscardin WJ, Kitchen SG, Alcantar JM, Smith JB, et
119. Pallikkuth S, Kanthikeel SP, Silva SY, Fischl M, Pahwa R, Pahwa S. Innate immune defects correlate with failure of antibody responses to H1N1/09 vaccine in HIV-infected patients. J Allergy Clin Immunol 2011; 128:1279-85; PMID:21752440; http://dx.doi.org/10.1016/j.jaci.2011.05.033.
120. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357:1903-15; PMID:17989383; http://dx.doi.org/10.1056/NEJMoa066092.
121. Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008; 197:1419-26; PMID:18444799; http://dx.doi.org/10.1086/587695.
122. Moir S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010; 116:5571-9; PMID:20837780; http://dx.doi.org/10.1182/blood-2010-05-285528.
123. Alachkar H, Taubenheim N, Haeney MR, Durandy A, Arkwright PD. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol 2006; 120:310-8; PMID:16782407; http://dx.doi.org/10.1016/j.clim.2006.05.003.
124. Gangappa S, Kokko KE, Carlson LM, Gourley T, Newell KA, Pearson TC, et al. Immune responsiveness and protective immunity after transplantation. Transpl Int 2008; 21:293-303; PMID:18225995; http://dx.doi.org/10.1111/j.1432-2277. 2007.00631.x.
125. Avigan D, Pirofski LA, Lazarus HM. Vaccination against infectious disease following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7:171-83; PMID:11302551; http://dx.doi.org/10.1053/bbmt.2001.v7. pm11302551.
126. Inaba H, Hartford CM, Pei D, Posner MJ, Yang J, Hayden RT, et al. Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2012; 156:109-17; PMID:22017512; http://dx.doi.org/10.1111/j.1365-2141. 2011.08913.x.
127. An earlier start for HIV therapy. Nat Med 2009; 15:848; PMID:19661988; http://dx.doi.org/10.1038/nm0809-848.
128. Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 2012; 30:4907-20; PMID:22658928; http://dx.doi.org/10.1016/j.vaccine.2012.05.049.
129. Tebas P, Frank I, Lewis M, Quinn J, Zifchak L, Thomas A, et al.; Center for AIDS Research and Clinical Trials Unit of the University of Pennsylvania. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010; 24:2187-92; PMID:20616698; http://dx.doi.org/10.1097/ QAD.0b013e32833c6d5c.